Concepedia

Sandra Rojas-Caro

SR

4

Publications

577

Citations

4

H-Index

2005

Active since

Affiliations

Synageva BioPharma (United States)(Current)

Alexion Pharmaceuticals (United States)

Gazi University

University of Manchester

Sandra Rojas-Caro is an author at Synageva BioPharma (United States) specializing in translational medicine, pathology, and medicine.

Top concepts

Publications per year

2005–2018

4

Publications

4

A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency

Barbara K. Burton, Manisha Balwani, François Feillet et al. · New England Journal of Medicine · 2015 · 238 citations · Full text

The G0/G1 switch gene 2 is a novel PPAR target gene

Fokko Zandbergen, Stéphane Mandard, Pascal Escher et al. · Biochemical Journal · 2005 · 232 citations · Full text

Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study

Simon Jones, Sandra Rojas-Caro, Anthony Quinn et al. · Orphanet Journal of Rare Diseases · 2017 · 85 citations · Full text

Final results of the phase 1/2, open-label clinical study of intravenous recombinant human N-acetyl-α-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB

Chester B. Whitley, Suresh Vijay, Bert Yao et al. · Molecular Genetics and Metabolism · 2018 · 22 citations

, , +6

Rows per page

1–4 of 4